| Nome |
# |
|
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, file eb99cc56-d170-4e04-9da3-fdf46797d63f
|
772
|
|
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system, file e1dcb337-6139-7715-e053-1705fe0a6cc9
|
469
|
|
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections, file e1dcb338-409c-7715-e053-1705fe0a6cc9
|
233
|
|
Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap, file 7fe50c66-e4bd-49ad-87d5-e086671af9b5
|
197
|
|
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence, file 754fdb08-fc73-488c-a9c4-cd9a6faac209
|
192
|
|
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia, file b7525bda-7bb4-4718-9aa2-dcab99f2cc9b
|
139
|
|
A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis, file 0b283948-9a2e-42a1-9e83-7b906fe1d196
|
135
|
|
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients, file 347e9aeb-6eb5-4cd3-8ac6-8e24d7929344
|
103
|
|
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF), file cec3b43a-b0ff-4621-90df-1e530b4abcd5
|
70
|
|
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring, file e1dcb33a-0f7c-7715-e053-1705fe0a6cc9
|
58
|
|
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings, file e1dcb339-f90b-7715-e053-1705fe0a6cc9
|
54
|
|
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol, file e1dcb33a-35af-7715-e053-1705fe0a6cc9
|
53
|
|
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections, file 713434bd-a8ec-4b5f-bdb5-c3a82676d1f5
|
49
|
|
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae, file e0a73cde-7327-4fc9-ba64-16072d7cd0e2
|
40
|
|
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb336-bed1-7715-e053-1705fe0a6cc9
|
38
|
|
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation, file 78eff9c8-ff6b-4976-bc78-1b8f4cb55958
|
37
|
|
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics, file 889755bb-05f6-4b45-8d1f-1ba788616b38
|
31
|
|
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file cf7d8fc4-5a7e-40a8-a176-6b5dab7929fe
|
26
|
|
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization, file ad8f2b9e-1fd3-40db-bc05-788a124d961b
|
24
|
|
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections, file b5a9c381-bdd6-4da1-b3dc-a1168a662588
|
24
|
|
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem, file fb09589a-3edf-4f74-9767-d2bb8ed6a38b
|
22
|
|
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, file 28c2f26d-ce73-4fb5-babf-66681de692e8
|
20
|
|
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal, file 69f80cdd-a0a4-4c80-80bc-ab3e66a45bce
|
19
|
|
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis, file 801f47a3-8df4-422f-aee9-59e29d44285b
|
19
|
|
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, file 8a74c889-69c7-402d-970d-db76ac58b4e9
|
19
|
|
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients, file d0ed9893-3d3e-4e9c-a036-f90463940bed
|
19
|
|
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring, file ae28784b-06a0-4994-841c-bad3c821fb5a
|
18
|
|
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, file e1dcb339-4230-7715-e053-1705fe0a6cc9
|
18
|
|
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient, file d636a18b-826e-4775-b999-9119744b6eec
|
17
|
|
European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study, file 08f94740-858d-4530-9a0a-20e950a70f9d
|
16
|
|
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis, file 36f230e0-ae1a-4654-902f-423fea08cf99
|
16
|
|
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases, file a678c401-1206-41b4-81b6-f059ae192e6d
|
16
|
|
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing, file e1dcb335-f4d5-7715-e053-1705fe0a6cc9
|
16
|
|
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients, file 73b3aa7d-37ec-47a1-a902-50cd20285808
|
15
|
|
Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice, file 95543ee5-ec0a-4ab8-89f1-bf0b400f1f35
|
15
|
|
Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities, file c8ab7b1c-d59b-4730-a2f0-51cb734ae8e2
|
15
|
|
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections, file cccc4cf4-0488-4777-a771-bbe07b110329
|
15
|
|
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study, file e1dcb339-7005-7715-e053-1705fe0a6cc9
|
15
|
|
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb339-da19-7715-e053-1705fe0a6cc9
|
14
|
|
Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience, file 17a1d748-d86e-4090-b092-5eca77bcb33a
|
12
|
|
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring, file 85da134a-ce59-431a-89f2-30a11d855824
|
12
|
|
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, file e1dcb336-c7d6-7715-e053-1705fe0a6cc9
|
12
|
|
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring, file 4d2d1fe9-5e78-4b29-939f-e9706942ab60
|
11
|
|
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis, file 059920ee-c806-4c30-a887-38f4c57907cf
|
10
|
|
Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues, file 54fbd2ad-8537-4afa-9e21-9b77219d0f86
|
10
|
|
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, file 682d5bcd-e075-47cf-8b73-1681beb917b8
|
10
|
|
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia, file e1dcb336-6202-7715-e053-1705fe0a6cc9
|
10
|
|
Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs, file ee9d1bde-7945-499f-8d89-55467c6ff6b9
|
10
|
|
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections, file 57e77ad7-08c0-40a6-aa55-d244a166ae9c
|
9
|
|
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, file c0395b8a-a717-4186-aa67-37c2b908c849
|
9
|
|
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis, file 179816c5-e9d7-4c17-8984-2ce768475d8e
|
8
|
|
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study, file e1dcb334-0b54-7715-e053-1705fe0a6cc9
|
8
|
|
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, file 7a76f612-27e6-4fff-b791-a1bf5aa6142b
|
6
|
|
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients?, file e5741841-380c-4ce7-ae53-bc35b8c478fc
|
6
|
|
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study, file 1d412cb7-9fc9-4a10-9468-a5ca74ed6da4
|
5
|
|
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system, file e1dcb336-f68a-7715-e053-1705fe0a6cc9
|
5
|
|
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study, file f684493e-2349-479a-9fda-fb131a2c4d36
|
5
|
|
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, file 283fb261-c43d-4dd8-8c7a-5af22d135f22
|
4
|
|
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration, file 6159e940-fe18-4ec5-8a62-f970c62f109a
|
4
|
|
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia?, file a3abbbc1-2718-4484-853b-47aa4e480c00
|
4
|
|
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f36-7715-e053-1705fe0a6cc9
|
4
|
|
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections, file 530f5a23-2e92-46d0-af71-30206d80f269
|
3
|
|
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis, file d1f61c47-249c-4759-982f-56a112d821a4
|
3
|
|
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f37-7715-e053-1705fe0a6cc9
|
3
|
|
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae, file 07bdcec3-b305-49ce-ae1b-9b46ad7f21d7
|
2
|
|
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring, file 1a270502-7717-48e6-bdc0-3356e6232909
|
2
|
|
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file 1be23e9b-59ba-4baf-936b-bd717c99497f
|
2
|
|
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan, file 1edba6e9-2ae9-4ea7-8077-0aa6a468075a
|
2
|
|
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis, file 269d5122-3a5f-4659-9526-73656a37f473
|
2
|
|
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP, file 4c293d8c-249a-449d-aab3-1b6322889d27
|
2
|
|
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies, file 4d0fd45c-44fd-41af-a935-95096d542061
|
2
|
|
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions, file 58ac1a96-dbb1-4ba1-9344-79fe214131a8
|
2
|
|
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections, file 68caa8f6-5a4b-4426-bf38-13c5c4d45a41
|
2
|
|
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies, file d5a912f4-315b-4939-a2de-a6ac15efed9f
|
2
|
|
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach, file fd598798-06ba-4ff2-ab53-e31e5bdef992
|
2
|
|
Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice, file 23af4084-6c9f-445c-8231-2c8ba97ee047
|
1
|
|
The European List of Key Medicines for Medical Education: A Modified Delphi Study, file 2c5b835a-8042-4d39-a109-b7df63c8ecc0
|
1
|
|
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections, file 642e26dd-9c6b-4bf5-92c4-013ad651322a
|
1
|
|
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future, file 7af826b3-d9ba-4b13-9674-a7dd41d83d97
|
1
|
|
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates, file a2aa789b-3c7f-42a6-a197-170470c7ab25
|
1
|
|
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia, file a38b13ed-1c2d-4c79-9aaa-b29e2010ff3a
|
1
|
|
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections, file af435912-0c36-4895-a2ef-6350e3916b61
|
1
|
|
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis, file bae44f5d-ebc1-469d-b401-543bde50858e
|
1
|
|
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study), file cd83248b-9363-423b-b046-6e24b959ac5a
|
1
|
|
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis, file cdf83cf2-c413-4027-bc3e-8ee90739933b
|
1
|
|
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia, file fdcd281f-8a15-4afe-82b0-e42d331c4ed0
|
1
|
| Totale |
3.284 |